Scott Gottlieb
CHICAGO — FDA officials are taking several steps designed to make the drug development review process more efficient while reducing costs and creating more opportunities for innovation, according to agency Commissioner Scott Gottlieb, MD.
Those strategies — which Gottlieb outlined during remarks at ASCO Annual Meeting — relate to all aspects of the continuum, including clinical trial recruitment, application submission and evaluation, and postmarket data collection.
“There are more reasons than ever for [patients with cancer] to expect to live longer lives,
Uncategorized